February 14th 2025
The transaction includes abelacimab, which is a late-stage medicine that is in development for prevention of stroke and systemic embolism in patients with atrial fibrillation.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Cell Culture Optimization—Part Two
December 23rd 2024Bob Schrock, PhD, senior director, global head of Process Development, at Lonza provides insight on how process controls change during development through commercialization, how cell harvesting can be optimized, and which validation and/or qualification studies are performed for cell culture.
The Future of mRNA–LNP Formulation Development (Part Two)
December 17th 2024In part two of a video interview, Colin McKinlay, PhD, senior director, Chemistry and Delivery Technologies, at Nutcracker Therapeutics, talks on current trends and the direction that mRNA–LNP development may take going forward.
Meeting the Challenges of mRNA and LNP Manufacturing (Part One)
December 14th 2024In a discussion on mRNA and LNP development, Colin McKinlay, the senior director of Chemistry and Delivery Technologies at Nutcracker Therapeutics, points out current challenges and innovations that meet these challenges.